Clinical Scorecard: Patient Satisfaction in Relapsing-Remitting Multiple Sclerosis: Benefits of Home-Based Self-Administration of Subcutaneous Ofatumumab Compared to Other High-Efficacy Treatments

At a Glance

Key Highlights

• Self-administration of ofatumumab at home linked to higher patient satisfaction.
• Less than 25% of patients offered home self-administration of high-efficacy therapy.
• Patient preferences increasingly important in therapeutic decision making.
• Diversity in administration routes affects treatment satisfaction and adherence.
• Need for comprehensive evaluations of patient satisfaction with high-efficacy therapies.

Guideline-Based Recommendations

Diagnosis

• Consider disease severity and prior treatment response in therapeutic decision making.

Management

• Incorporate patient preferences and lifestyle factors in treatment selection.

Monitoring & Follow-up

• Utilize structured patient-reported measures to assess treatment satisfaction.

Risks

• Address logistical and organizational considerations in treatment administration.

Patient & Prescribing Data

Adults with relapsing-remitting MS receiving high-efficacy therapies for at least 6 months.

Home self-administration may reduce treatment burden and improve quality of life.

Clinical Best Practices

• Evaluate patient-reported outcomes to inform treatment decisions.
• Facilitate shared decision making regarding treatment administration routes.
• Consider psychosocial factors influencing patient adherence.

References

• Multiple Sclerosis International Federation